MedTrace Logo

Effects of Isocapnic Respiratory Muscle Endurance Training in Healthy Adults

NCT07103291 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2026-05-15

No results posted yet for this study

Summary

Respiratory muscle training (RMT) strengthens breathing muscles and may improve exercise performance and reduce breathlessness. However, different training methods and devices create controversy in the field. Two main types of RMT exist: inspiratory muscle training (IMT) and respiratory endurance training, like voluntary isocapnic hyperpnea (VIH). While IMT is well-studied, the impact of VIH on breathlessness remains unclear. This study will use the Canadian-developed BreathWayBetter device to examine how 5 weeks of VIH affects breathing discomfort and muscle function. Findings may help personalize RMT for athletes and clinical patients, improving respiratory care and exercise tolerance.

Conditions

  • Healthy Adults

Interventions

OTHER

Respiratory muscle endurance training

Respiratory muscle endurance training program over 5 weeks.

OTHER

Sham respiratory muscle endurance training

Respiratory muscle endurance training program over 5 weeks following a sham training procedure that is meant to elicit no physiologic changes.

Sponsors & Collaborators

  • Mitacs

    collaborator INDUSTRY

  • University of British Columbia

    lead OTHER

Principal Investigators

  • Jordan Guenette, PhD · University of British Columbia

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-08-04
Primary Completion
2026-08-01
Completion
2026-08-01

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07103291 on ClinicalTrials.gov